Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PDUFA VI: FDA Proposes Expanding Sentinel, Real-World Safety Data Sources

This article was originally published in The Pink Sheet Daily

Executive Summary

Growth of post-market surveillance system also may require more resources.

You may also be interested in...

FDA Aims To Tap Sentinel Data Network For Drug Effectiveness Studies

New ‘Guardian’ program to monitor post-market effectiveness through the Sentinel electronic data network will take five years to build, FDA’s Woodcock says.

Califf Continues Clinical Trial Reform Crusade With Confirmation Vote Pending

FDA Commissioner nominee outlines ideas for improving clinical trials in written responses to senators' questions; HELP Committee to vote Jan. 12.

Drisapersen Advisory Committee Is Rough Welcome To FDA For Patient Groups

Advocates counter FDA’s problems with Duchenne muscular dystrophy treatment's trial data using real-life experience.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts